LLY Stock Draws Retail Buzz – Here’s Why Its Investigational Drug Retatrutide Became The Talk Of The Town

• Retatrutide showed improvements in key cardiovascular risk factors, including cholesterol and blood pressure.
• The company stated that the primary side effects were mild to moderate gastrointestinal issues such as nausea and diarrhea.
• Lilly’s SURPASS-1 trial to test Tirzepatide showed the drug lowering blood sugar by up to 2.07% and weight by up to 9.5 kg.

Eli Lilly and Company (LLY) caught investors’ attention after the pharmaceutical company reported strong Phase 3 results for its experimental drug Retatrutide to treat patients with type 2 diabetes.

Drug developers are racing to tap the booming obesity market, currently led by injectables like Wegovy from Novo Nordisk and Lilly’s own Zepbound. Retatrutide is a once-weekly injectable activating three hormone receptors - GLP-1, GIP ​and glucagon.

According to a Bloomberg article on Thursday, analysts see potential sales of Retatrutide exceeding $10.6 billion by 2036. LLY stock was little changed at the time of writing.

Retatrutide Trial Meets Key Endpoints

In the TRANSCEND-T2D-1 trial, Retatrutide met all key endpoints, showing better blood sugar control and weight loss than placebo after 40 weeks. A1C levels, a measure of blood sugar, dropped by up to 2%, while patients lost an average of up to 36.6 pounds, or around 17 kg. Notably, weight loss continued throughout the treatment period without slowing down.

Retatrutide also showed improvements in key cardiovascular risk factors, including cholesterol and blood pressure. The most common side effects were mild to moderate gastrointestinal issues such as nausea and diarrhea.

“With triple agonist Retatrutide, we set out to make a molecule that could help patients achieve substantial A1C reduction and weight loss. These results support the remarkable potential of this novel molecule for people living with type 2 diabetes, with up to 2% A1C improvement and nearly 17% weight loss in 40 weeks of treatment,” said Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health.

Comparatively, Lilly’s SURPASS-1 trial to test Tirzepatide, sold under Mounjaro and Zepbound brands, showed the drug lowering blood sugar by up to 2.07% and weight by up to 9.5 kg.

How Did Stocktwits Users React?

Retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, amid ‘high’ message volumes.

One user compared Tirzepatide and Retatrutide trials.

Another user believes Lilly is a “clear leader”

Year-to-date, the stock is down 15%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.